User Name:

Password:

remember me

Forgot your password?

Not a member?

Join Now

News Topic - Pfizer

RSS feedDisplaying articles 1 - 10 of most recent articles

Photo from Yahoo! News
Merck, Pfizer drug combo extends kidney cancer survival: study Nearly 90 percent of patients who received the combination therapy were still alive after 12 months compared with about 78 percent of patients who were alive after a year when treated with the older drug Sutent, data showed. Merck on Monday released inter
Yahoo! News | 18 hours, 37 minutes ago | comment? | recommend
Bayer stresses drug's tolerability in bid for prostate cancer market Bayer is banking on the mild side effects of its experimental prostate cancer drug darolutamide, as it prepares to take on established rival products by Pfizer and Johnson & Johnson.
Reuters | Feb 14, 2019 9:48 PM [GMT] | comment? | recommend
Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.
Yahoo! News | Feb 12, 2019 3:10 PM [GMT] | comment? | recommend
Better Buy: Gilead Sciences vs. Pfizer Which of these drugmakers will push your portfolio higher in the years ahead?
Fool.com | Feb 12, 2019 12:17 PM [GMT] | comment? | recommend
Photo from Yahoo! News
Merck, Pfizer combo treatment boosts kidney cancer survival Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemo
Yahoo! News | Feb 12, 2019 01:02 AM [GMT] | comment? | recommend
FDA Accepts sBLA and Grants Priority Review for BAVENCIO (avelumab) Plus INLYTA (axitinib) for the Treatment of Advanced Renal Cell Carcinoma ROCKLAND, Massachusetts and NEW YORK, Feb. 11, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FD
PR Newswire | Feb 11, 2019 10:44 PM [GMT] | comment? | recommend
Photo from Yahoo! News
Pfizer Japan recalls high blood pressure drug over cancer-causing impurity The Japanese subsidiary of Pfizer Inc is recalling a drug for high blood pressure which was found to contain a carcinogenic substance in its active ingredient valsartan, the drugmaker said on Friday. More than 763,000 tablets of the drug Amvalo, manufactu
Yahoo! News | Feb 9, 2019 02:57 AM [GMT] | comment? | recommend
At least four pharma CEOs to testify at Senate drug pricing hearing Drugmakers Pfizer Inc, Bristol-Myers Squibb Co and Sanofi SA said on Wednesday that their chief executives plan to testify at a Senate hearing on rising prescription drug prices later this month.
Reuters | Feb 6, 2019 10:48 PM [GMT] | comment? | recommend
Pfizer CEO Bourla plans to testify at Senate drug pricing hearing U.S. drugmaker Pfizer Inc said on Wednesday that its Chief Executive Albert Bourla plans to testify later this month at a Senate hearing examining rising prescription drug prices.
Reuters | Feb 6, 2019 2:55 PM [GMT] | comment? | recommend
Photo from WebWire
The Union for International Cancer Control and Pfizer Announce New Phase of Global Grants Initiative Supporting Metastatic Breast Cancer Patients In conjunction with World Cancer Day, the Union forInternational Cancer Control (UICC) and Pfizer Inc. announce the third round of the S eeding P rogress A nd R esources for the C ancer Community (SPARC): Metastatic Breast Cancer (MBC) Challenge: theirpio
WebWire | Feb 5, 2019 9:18 PM [GMT] | comment? | recommend